Pascal Juillerat MD MSc, IBD specialist

Great lucter abt Acute Severe & Fulminant Colitis by @PascalJuillerat Masterclass in IBD 💚 supervised by @DignassAxel & Stephan Vavricka @my_ueg EDUCATION 💙 Vienna 🎡 2025 #UEG 💜 #IBD #UC #ASCU .

🤩 exciting days ahead

Great talk by Bel Kok regarding disease monitoring in IBD at @my_ueg IBD masterclass

Course Directors: @DignassAxel, @VavrickaStephan Faculty: @ign76, @Bealoquebea, @DrAilsaHart, @PascalJuillerat, Bel Klaartje Kok, James Lindsay, @PMyrelid, @edyta_tul, @bverstockt

AGA 2025 clinical practice guidelines for Crohn’s disease 📌🆕 📸: gastrojournal.org/action/showPdf…

'Free to read' via bit.ly/45GWWRG "Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease" by Mahadevan et al #IBD #GItwitter #pregnancy

We’re pleased to announce the “ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with IBD,” a project involving IBUS, showing the role of IUS in the diagnosis and monitoring of IBD patients. P.1: 10.1093/ecco-jcc/jjaf106 P.2: 10.1093/ecco-jcc/jjaf107

Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…

Just Starting 4th Postgraduate Course #ECCO2025 #EDUCOM course with more than 350 attendees! @UriKopylov @FernandoMagro6 with and a amazing talk from @SeverineVermei1

Thank you for your contribution to this Great case discussion and long Life to the PG of ECCO ! @manu_barreiro @Iagorlago @UriKopylov #ECCO2025

New IBD classification. Florence classification @doc_ibd @IBDCedarsSinai #ECCO2025

Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial ➡️ ow.ly/qY1950UX0ZO

Just published in the American Journal of Therapeutics 🔥 JAKi in Chronic Inflammatory Pouch Conditions: 📌Clinical response: 43% 📌Endoscopic response: 48% 📌AEs: 16% 📌Primary treatment failure: 42% 📊JAKi are not recommended to be first line treatment in chronic pouch conditions ✔️ @JHashashMD @fouadsjaber @YazanAbboudMD @CrohnsColitisFn #GITwitter #IBD @MondayNightIBD

Completely agree ! Amazing meeting and conclusions, congratulations! @EdwardLoftus2 @MLongMD @MRegueiroMD @DrCoreySiegel @NMH_SHanauerMD #AIBD2024

How can you not love Charles Bernstein ? Amazing career as a clinician scientist for over 30 years!!! Linking the learnings from IBD epidemiology to climate inform clinical practice @gilkaplan @EdwardLoftus2

#ECCO UC Treatment Guideline Update - how it started... @bverstockt @HolubarStefan @RajaAtreya @I_Blumenstein @AlaaEl_Hussuna @manu_barreiro @AnthonydeBuck @fgomollon @Max_Fantini @fede__furfaro @MariangelaAllo3 @PascalJuillerat @mjosecasanova @UriKopylov @EderPiotr et al. #IBD

IBD Monitoring how&when. Tandem talk with #HagarBanaiEran from #rabinhospitalpetahtikva at #FalkSymposium238 in Florence. ⁦@HUNIMED⁩

Luc Biedermann at #Falksymposium238 presenting on biological treatments in EoE. @IBD_USZ , Great job.

🌟 Making a choice of therapy for IBD Take into account extraintestinal concerns as well as contraindications to treatment! 🙏🏻 @IBDMD #GITwitter #ACG2024 @AmCollegeGastro

Nobel Prize winning concepts land in IBD. The discovery of power and importance of microRNA biology . @bruce_sands1 presenting the long term results of the phase 2a Obefazimod UC. Study . Is this the game changer? Calling all investigators . We need to get the phase III DONE !!!